XENOPORT INC COM (XNPT) : Asymmetry Capital Management scooped up 331,850 additional shares in XENOPORT INC COM during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 21, 2016. The investment management firm now holds a total of 1,627,628 shares of XENOPORT INC COM which is valued at $8,007,930.XENOPORT INC COM makes up approximately 18.93% of Asymmetry Capital Management’s portfolio.
XENOPORT INC COM closed down -0.14 points or -2.93% at $4.64 with 2,39,474 shares getting traded on Wednesday. Post opening the session at $4.76, the shares hit an intraday low of $4.62 and an intraday high of $4.8 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.
Other Hedge Funds, Including , Next Financial Group Inc added XNPT to its portfolio by purchasing 1,300 company shares during the most recent quarter which is valued at $6,396. Acadian Asset Management sold out all of its stake in XNPT during the most recent quarter. The investment firm sold 63,211 shares of XNPT which is valued $312,262.Simplex Trading reduced its stake in XNPT by selling 6,700 shares or 82.35% in the most recent quarter. The Hedge Fund company now holds 1,436 shares of XNPT which is valued at $7,094.Creative Planning reduced its stake in XNPT by selling 1,353 shares or 54.12% in the most recent quarter. The Hedge Fund company now holds 1,147 shares of XNPT which is valued at $5,506.
On the company’s financial health, XENOPORT INC COM reported $-0.21 EPS for the quarter, beating the analyst consensus estimate by $ 0.07 according to the earnings call on Feb 25, 2016. Analyst had a consensus of $-0.28. The company had revenue of $14.07 million for the quarter, compared to analysts expectations of $13.74 million. The company’s revenue was up 98.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.28 EPS.
XenoPort Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the treatment of neurological and other disorders. The Company is commercializing HORIZANT (gabapentin enacarbil) Extended-Release Tablets in the United States and REGNITE (gabapentin enacarbil) Extended-Release Tablets is being marketed in Japan by Astellas Pharma Inc. (Astellas). The Company’s development-stage product candidates include XP23829 a fumaric acid ester product candidate XP21279 and arbaclofin placarbil (AP). HORIZANT is used for the treatment of primary restless legs syndrome (RLS) and for the management of postherpetic neuralgia (PHN). XP23829 is a fumaric acid ester compound and a prodrug of monomethyl fumarate (MMF) which has completed Phase I clinical trials. XP21279 is a transported prodrug of levodopa for the treatment of patients with idiopathic Parkinson’s disease and has completed Phase II clinical trials.